Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Gilead's Remdesivir Sold Out Already
08:22am, Thursday, 02'nd Jul 2020
Remdesivir pricing allows revenue calculations. The last allocation of 120,000 donated courses shipped on Monday. The U.S. has bought the world's supply of remd
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.6% After Analyst Upgrade
01:10am, Wednesday, 01'st Jul 2020
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 4.6% during mid-day trading on Monday after JMP Securities raised their price target on the stock from $10.00 to $11.00. JMP Securities curr
Top Stocks To Short As Dow Surges From Boeing Gains
12:00am, Monday, 29'th Jun 2020
As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you tod
Why BioCryst Pharmaceuticals Stock Jumped Today | The Motley Fool
07:50pm, Friday, 26'th Jun 2020
An analyst upped his price target for the drugmaker.
Implied Volatility Surging for BioCryst (BCRX) Stock Options
12:53pm, Thursday, 18'th Jun 2020
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
Hedge Funds Have Never Been This Bullish On BioCryst Pharmaceuticals, Inc. (BCRX)
11:43am, Monday, 15'th Jun 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
BioCryst Berotralstat PDUFA, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BCRX)
06:42pm, Thursday, 11'th Jun 2020
BioCryst's Berotralstat PDUFA has been set for December 3, 2020. Sarepta progresses with muscular dystrophy study. Aimmune's Palforzia produces positive data.
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late (NASDAQ:ALXN)
06:44pm, Wednesday, 10'th Jun 2020
The patent disputes over the leading drug forced Alexion to seek the revenue diversification. The recent acquisitions are unlikely to accelerate the current gro
Galidesivir Stops Zika Viral Replication in Primate Model
06:00pm, Wednesday, 10'th Jun 2020
BioCryst Pharmaceuticals, Inc. (BCRX) today announced new data published in Science Translational Medicine show, in a primate model, that galidesivir was safe, provided post-exposure prevention of Zik
BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States
08:15pm, Tuesday, 09'th Jun 2020
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has established an expanded access program (EAP) with oral, once-daily berotralstat, an investigational drug, for patients with h
Here's Why BioCryst Pharmaceuticals Jumped 15% in May
07:40pm, Monday, 08'th Jun 2020
Berotralstat is under review by the Food and Drug Administration, with a decision expected on or before Dec. 3. Regulators in Japan are expected to make a decision in the second half of 2020, and a d
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication
07:01am, Saturday, 06'th Jun 2020
BioCryst Pharmaceuticals, Inc. (BCRX) today presented findings from two patient surveys conducted to gain insights into patients’ current hereditary angioedema (HAE) treatment expectations, experie
BioCryst Pharmaceuticals, Inc. (BCRX) today announced new data from the APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily berotralstat e
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:15am, Tuesday, 02'nd Jun 2020
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an a
RESEARCH TRIANGLE PARK, N.C., June 01, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447.
